Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents.
The high distribution of CB(2) receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: CB(2) selective agonists are able to modulate inflammation without triggering psychotropic effects. This review will summarize the literature on the implication of CB(2) in inflammation and CB(2) selective agonists with anti-inflammatory activity.
Institut de Chimie Pharmaceutique Albert Lespagnol, Université Lille Nord de France, EA 4481, IFR114, 3 rue du Pr. Laguesse, B.P. 83, F-59006 Lille, France.
N
N
Leleu-Chavain
M
M
Body-Malapel
J
J
Spencer
P
P
Chavatte
P
P
Desreumaux
R
R
Millet
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D015394:Molecular Structure; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists* / Q000276:immunology; D013329:Structure-Activity Relationship
D000894:Anti-Inflammatory Agents, Non-Steroidal; D043885:Receptor, Cannabinoid, CB2